O&G Vivas · Antenatal care — genetic screening
Genetic carrier screening — structured oral station (12 minutes)
FRANZCOG oral-format station on reproductive carrier screening: candidate explains the three-gene panel, the inheritance and risk, the timing rationale, and counsels a both-partner positive result non-directively. Scored against the eight published RANZCOG oral domains.
On this page
Study tools
Target exams
FRANZCOGMRCOGABOG
Prompt
You are the registrar in pre-pregnancy clinic. A 27-year-old woman and her partner, both healthy with no family history of genetic disease, ask whether they should be 'tested for genetic conditions' before trying to conceive. The examiner will ask you to explain carrier screening, defend who and when to screen, and counsel a result.
Station format
4 minutes reading, 12 minutes examination, 20 marks, global scoring. The eight published RANZCOG oral domains apply to every station: history and examination; investigations and interpreting results; treatment and management; clinical knowledge; complex, urgent or unusual clinical presentations; rapport; respect; communication. [1]
Reveal the examiner script and model responsesShowHide
Opening prompt — "Tell me what you would say to them."
Model response: [1]
- "Carrier screening is a blood test that tells us whether you carry a gene change that, if your partner carries the same one, could cause a serious condition in a child. Most affected children are born to couples with no family history, which is why we offer it to everyone."
- "The standard panel looks at three conditions: cystic fibrosis, spinal muscular atrophy and fragile X. Carrier frequencies are about 1 in 25, 1 in 40 and 1 in 250 women respectively."[1]
- "We do it before you conceive, because a result known now keeps every option open — including IVF to select unaffected embryos. I would test the woman first, and her partner only if she is a carrier."[1]
Probe 1 — "Why before conception? Why not at the booking visit?"
- "Because the options change. Before conception, a positive result lets a couple choose IVF with pre-implantation genetic testing, donor gametes, or not to conceive. Once pregnant — especially past the first trimester — we are left with prenatal diagnosis and a possible termination, which is a narrower, harder set of choices."[1]
Probe 2 — "She asks: if the test is negative, does that mean no risk?"
- "No — and this is important. A negative screen greatly reduces the risk but does not bring it to zero, because the panel detects the common variants but not every rare one. There is always a residual risk, and I would tell her that."[1][6]
Probe 3 — "The result comes back: both of them are carriers of spinal muscular atrophy. What do you do?"
- "Refer to clinical genetics, and lay out the reproductive options, without directing them to one: accept the one-in-four risk; natural conception with prenatal diagnosis and the option of termination; IVF with pre-implantation genetic testing; donor gametes; or adoption. The choice is theirs, supported by counselling on what SMA means for a child."[1]
Probe 4 — "Now her own result is a fragile X premutation. Does that change anything?"
- "Yes — fragile X is different. As well as the reproductive risk to a future child, a premutation has implications for her: an increased risk of fragile-X-associated primary ovarian insufficiency, with reduced fertility and earlier menopause, and her relatives may carry it too. We offer cascade testing of the family and discuss her ovarian reserve."[9]
Probe 5 — "They are overwhelmed. Counsel them."
This is a scored domain. Demonstrate it out loud: [1]
- Move to their eye level, use their names, validate the overwhelm: "It is a lot to take in, and we will go at your pace."
- Brief plainly: "Being a carrier is not an illness — it just means we plan. You have options, and our genetics team will walk through every one with you. There is no rush and no right answer."
- Offer a written summary, a follow-up appointment, and the genetic counsellor contact.[1]
References3ShowHide
- [1]Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Genetic Carrier Screening (C-Obs 63), Interim Update July 2024 RANZCOG Statement, 2024.Source
- [9]Morbey EJ, Day FR, Wright DJ, et al. Large-scale analysis of FMR1 CGG repeat length and risk of premature ovarian insufficiency in over 92 000 women Hum Reprod, 2026.PMID 42001465
- [6]Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening Genet Med, 2013.PMID 23619275